73,163 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by F M Investments LLC

F M Investments LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 73,163 shares of the specialty pharmaceutical company's stock, valued at approximately $2,096,000. F M Investments LLC owned approximately 0.23% of Collegium Pharmaceutical as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of COLL. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $40,000. TD Private Client Wealth LLC grew its holdings in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after acquiring an additional 483 shares in the last quarter. KBC Group NV grew its holdings in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after acquiring an additional 982 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares in the last quarter.

Remove Ads

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded up $0.39 during trading on Tuesday, reaching $27.12. The company had a trading volume of 358,999 shares, compared to its average volume of 443,989. The company has a market capitalization of $871.42 million, a PE ratio of 11.69 and a beta of 0.76. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm's 50 day simple moving average is $29.06 and its two-hundred day simple moving average is $31.47. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Activity

In related news, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,693 shares of company stock valued at $2,334,994. 3.98% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on COLL shares. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. Needham & Company LLC restated a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. StockNews.com upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.